¼¼°èÀÇ ÀÚ±â ¸ÅÆ®¸¯½º À¯µµ ¿¬°ñ Çü¼º(AMIC) ½ÃÀå
Autologous Matrix-Induced Chondrogenesis (AMIC)
»óǰÄÚµå : 1507900
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 214 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,026,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,080,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÚ±â ¸ÅÆ®¸¯½º À¯µµ ¿¬°ñ Çü¼º(AMIC) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 2¾ï 7,800¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 1¾ï 6,440¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÚ±â ¸ÅÆ®¸¯½º À¯µµ ¿¬°ñ Çü¼º(AMIC) ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ 2023-2030³â¿¡ CAGR 7.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2¾ï 7,800¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Äݶó°ÕÀº CAGR 7.5%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á ½Ã 1¾ï 5,880¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. È÷¾Ë·ç·Ð»ê ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5,280¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í Áß±¹Àº CAGR 9.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ÀÇ ÀÚ±â ¸ÅÆ®¸¯½º À¯µµ ¿¬°ñ Çü¼º(AMIC) ½ÃÀåÀº 2023³â 5,280¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2023-2030³â°£ CAGR 9.9%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 2,610¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 6.4%¿Í 7.3%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 8.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ÀÚ±â ¸ÅÆ®¸¯½º À¯µµ ¿¬°ñ Çü¼º(AMIC) ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

ÀÚ±â ¸ÅÆ®¸¯½º À¯µµ ¿¬°ñ Çü¼º(AMIC)Àº °üÀýÀÇ ¿¬°ñ °á¼ÕÀ» Ä¡·áÇϱâ À§ÇØ °³¹ßµÈ Çõ½ÅÀûÀÎ ¼ö¼ú ¹æ¹ýÀÔ´Ï´Ù. ÀÌ ¼ö¼ú ¹æ¹ýÀº ¿¬°ñ Çϰñ¿¡ ÀÛÀº ±¸¸ÛÀ» ¿­¾î Ç÷·ù¿Í ¼¼Æ÷ À̵¿À» ÀÚ±ØÇÏ´Â ¸¶ÀÌÅ©·Î ÇÁ·¢Ã³ ¼ö¼ú°ú »ýü ÀûÇÕ¼º Äݶó°Õ ¸·ÀÇ Àû¿ëÀ» °áÇÕÇÑ °ÍÀÔ´Ï´Ù. Äݶó°Õ ¸·Àº Áß°£¿± Áٱ⼼Æ÷¿¡¼­ ¿¬°ñ¼¼Æ÷·ÎÀÇ Áõ½Ä°ú ºÐÈ­¸¦ Áö¿øÇÏ´Â ¹ßÆÇÀÌ µË´Ï´Ù. AMICÀº ÁÖ·Î ¹«¸­¿¡ »ç¿ëµÇÁö¸¸, °í°üÀý, ¹ß¸ñ, ¾î±ú µî ´Ù¸¥ °üÀý¿¡µµ ÀÀ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ¿¬°ñ ¼Õ»óÀ» º¹±¸Çϰí ÅëÁõÀ» ¿ÏÈ­ÇÏ°í °üÀý ±â´ÉÀ» °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·ÎÇϸç, Àڱ⠿¬°ñ ¼¼Æ÷ À̽Ä(ACI)°ú °°Àº ±âÁ¸ÀÇ ¿¬°ñ º¹±¸ ¹æ¹ýÀ» ´ëüÇϴ ħ½ÀÀÌ ÀûÀº ¹æ¹ý Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù.

AMIC ¼ö¼úÀº ¸ÕÀú °üÀý°æ ¼ö¼ú ¶Ç´Â ¹Ì´Ï ¿ÀÇ ¼ö¼ú·Î ¿¬°ñ °á¼ÕºÎ¿¡ Á¢±ÙÇÕ´Ï´Ù. ¼Õ»óµÈ ¿¬°ñÀ» ¹Ú¸®ÇÑ ÈÄ, ±× ¾Æ·¡ÀÇ »À¿¡ ¹Ì¼¼ °ñÀýÀ» ¸¸µé¾î Áٱ⠼¼Æ÷¸¦ dzºÎÇÏ°Ô ÇÔÀ¯ÇÏ´Â °ñ¼ö ¿ä¼Ò¸¦ ¹æÃâ½Ãŵ´Ï´Ù. ±×·± ´ÙÀ½ ÀϹÝÀûÀ¸·Î µÅÁö ¶Ç´Â ¼ÒÀÇ Äݶó°Õ ¸·À» ¹Ì¼¼ °ñÀý¿¡ µ¤°í ÇǺ기 Á¢ÂøÁ¦ ¶Ç´Â ºÀÇÕ»ç·Î °íÁ¤ÇÕ´Ï´Ù. ÀÌ ¸·Àº »õ·Î Çü¼ºµÈ ¿¬°ñÀ» º¸È£ÇÏ´Â ¹°¸®Àû À庮ÀÌ µÉ »Ó¸¸ ¾Æ´Ï¶ó Áٱ⼼Æ÷°¡ Áõ½Ä ¹× ºÐÈ­Çϴµ¥ ÃÖÀûÀΠȯ°æÀ» ¸¸µé¾î ³À´Ï´Ù. ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ÀÌ·¯ÇÑ ¼¼Æ÷´Â ±âÁ¸ ¿¬°ñ°ú ÅëÇÕ µÈ »õ·Î¿î ¿¬°ñ Á¶Á÷À» »ý¼ºÇÏ¿© Àå±â °üÀýÀÇ °Ç°­À» ÃËÁøÇÕ´Ï´Ù. AMICÀº ³·Àº ħ½ÀÀ̱⠶§¹®¿¡ ħ½À¼ºÀÌ ³ôÀº ¼ö¼ú¿¡ ºñÇØ ȸº¹ÀÌ ºü¸£¸ç ¼ö¼ú ÈÄ ºÒÄè°¨µµ Àû½À´Ï´Ù.

ÀÚ±â ¸ÅÆ®¸¯½º À¯µµ ¿¬°ñ Çü¼º(AMIC) ½ÃÀåÀÇ ¼ºÀåÀº ÀÇ·á ±â¼úÀÇ Áøº¸, °üÀý ¼Õ»óÀÇ À¯º´·ü Áõ°¡, È¿°úÀûÀÎ ¿¬°ñ º¹±¸ ¼Ö·ç¼Ç ¼ö¿ä¸¦ ¹Ý¿µÇÏ´Â ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. Áß¿äÇÑ ÃËÁø¿äÀÎ Áß Çϳª´Â ½ºÆ÷Ã÷ ¿Ü»ó°ú °ñ°üÀý¿°ÀÇ ÀÌȯÀ²ÀÇ »ó½ÂÀ̸ç, °üÀý ±â´ÉÀ» ȸº¹½Ã۰í ÅëÁõÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ýüÀç·á¿Í ¼ö¼ú±â¼úÀÇ ±â¼úÀû Áøº¸µµ AMICÀÇ Ã¤¿ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ÀýÂ÷ÀÇ È¿°ú¿Í ½Å·Ú¼ºÀ» ³ôÀ̱⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ °üÀý º¯¼º¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸ Áõ°¡´Â ¿¬°ñ º¹±¸ ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ³·Àº ħ½À ¼ö¼ú ±â¼ú·ÎÀÇ ÀüȯÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í Çâ»ó½Ã۰í ÀÖÀ¸¸ç, ȯÀڴ ȸº¹¿¡ ¼Ò¿äµÇ´Â ½Ã°£ÀÌ Âª°í À§ÇèÀÌ ÀûÀº ¼ö¼úÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´Ù¾çÇÑ Áö¿ªÀÇ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú À¯¸®ÇÑ »óȯ Á¤Ã¥µµ AMICÀÇ Ã¤¿ëÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº Á¾ÇÕÀûÀ¸·Î AMIC ½ÃÀåÀÇ È®´ë¿Í ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ¿© ÀÓ»ó ÇöÀå¿¡¼­ AMICÀÇ Áö¼ÓÀûÀÎ ÁøÈ­¿Í ä¿ëÀ» È®½ÇÈ÷ Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñÀÇ 28»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market to Reach US$278.0 Million by 2030

The global market for Autologous Matrix-Induced Chondrogenesis (AMIC) estimated at US$164.4 Million in the year 2023, is expected to reach US$278.0 Million by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Collagen, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$158.8 Million by the end of the analysis period. Growth in the Hyaluronic Acid segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$52.8 Million While China is Forecast to Grow at 9.9% CAGR

The Autologous Matrix-Induced Chondrogenesis (AMIC) market in the U.S. is estimated at US$52.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$26.1 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market - Key Trends & Drivers Summarized

Autologous Matrix-Induced Chondrogenesis (AMIC) is an innovative surgical technique developed to treat articular cartilage defects in joints. This procedure combines microfracture surgery, which involves creating small holes in the subchondral bone to stimulate blood flow and cell migration, with the application of a biocompatible collagen membrane. The membrane serves as a scaffold to support the growth and differentiation of mesenchymal stem cells into chondrocytes, which are the cells responsible for producing cartilage. AMIC is primarily used in the knee, but it can also be applied to other joints such as the hip, ankle, and shoulder. This technique aims to repair cartilage damage, reduce pain, and improve joint function, offering a less invasive alternative to traditional cartilage repair methods like autologous chondrocyte implantation (ACI).

The procedure for AMIC begins with arthroscopic or mini-open surgery to access the cartilage defect. After debriding the damaged cartilage, microfractures are created in the underlying bone to release bone marrow elements rich in stem cells. A collagen membrane, typically derived from porcine or bovine sources, is then placed over the microfractured area and secured with fibrin glue or sutures. This membrane not only provides a physical barrier to protect the newly forming cartilage but also creates an optimal environment for the stem cells to proliferate and differentiate. Over time, these cells generate new cartilage tissue that integrates with the existing cartilage, promoting long-term joint health. The minimally invasive nature of AMIC allows for quicker recovery times and less postoperative discomfort compared to more invasive procedures.

The growth in the Autologous Matrix-Induced Chondrogenesis (AMIC) market is driven by several factors, reflecting advancements in medical technology, increasing prevalence of joint injuries, and the demand for effective cartilage repair solutions. One significant driver is the rising incidence of sports injuries and osteoarthritis, which has heightened the need for innovative treatments that can restore joint function and alleviate pain. Technological advancements in biomaterials and surgical techniques have also contributed to the adoption of AMIC, as these improvements enhance the effectiveness and reliability of the procedure. Additionally, the growing aging population, which is more susceptible to joint degeneration, has led to increased demand for cartilage repair therapies. The shift towards minimally invasive surgical techniques further supports the market growth, as patients seek procedures with shorter recovery times and lower risks. Regulatory approvals and favorable reimbursement policies in various regions are also encouraging the adoption of AMIC. These factors collectively drive the expansion and innovation in the AMIC market, ensuring its continued evolution and adoption in clinical practice.

Select Competitors (Total 28 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â